CSIMarket


Iridex Corp  (IRIX)
Other Ticker:  
 


 

Iridex Corp

IRIX's Financial Statements and Analysis



Iridex Corp increased third quarter of 2023 net loss per share of $-0.11 compare to net loss per share of $-0.11 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.17 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.11 $  13 Mill
Unch.     $-2M     -12.72 %



Iridex's Revenue fell by -12.72 % in third quarter of 2023 (Sep 30 2023) year on year, to $13 million and advanced by 2.09 % sequentially.


Iridex is

More on IRIX's Income Statement



Iridex's in thethird quarter of 2023 recorded net loss of $-1.754 million, an improvement compare to net loss of $-1.767 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-2.766 million realized in previous quarter.

More on IRIX's Growth

Iridex Inventories
Inventories declined by -6.01 % to $10.12 million from III. Quarter a year ago, sequentially inventories fell by -9.08 %. In Sep 30 2023 company's net cash and cash equivalents decreased by $-2 million, capital expenditures fell by -0.05743.86%, to $0 millions compare to same quarter a year ago

More on IRIX's Cash flow Statement


Iridex Corp does not pay out common stock dividend.

In trailing twelve-month period Iridex Corp payed $ -0.45 cash per share, on a free-cash flow basis .

Book value fell by -11.38 % sequentially to $0.74 per share, -19.83% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.58 per share from $ 0.67.

Company issued 0.20 million shares or 1.22 % in Sep 30 2023.


More on IRIX's Dividends

 Market Capitalization (Millions) 41
 Shares Outstanding (Millions) 16
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Iridex Corp does not pay out common stock dividend.

In trailing twelve-month period Iridex Corp had negative $ -0.45 cash flow per share, on a free-cash flow basis .

Book value fell by -11.38 % sequentially to $0.74 per share, -19.83% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.58 per share from $ 0.67.

Company issued 0.20 million shares or 1.22 % in Sep 30 2023.


More on IRIX's Balance Sheets

 Market Capitalization (Millions) 41
 Shares Outstanding (Millions) 16
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 53
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Iridex Corp Earnings

IRIX Triumphs Over Obstacles, Shines in Q3 Earnings Season

Iridex Corp, a leading medical equipment and supplies company, recently released its financial results for the third quarter of 2023 earnings season. While the company reported a net loss of $-0.11 per share, this is an improvement compared to the previous year's loss of $-0.17 per share. However, the revenue for the quarter declined significantly by -12.718% to $12.62 million, compared to $14.46 million in the same period a year ago.
This decline in revenue is in stark contrast to the overall trend in the Medical Equipment and Supplies sector, which saw a top-line gain during the same period. The company's management has not provided specific reasons for this decline, but some experts speculate that it ...

Iridex Corp Shines Bright: Impressive Second Quarter 2023 Performance Leaves Competitors in Awe

Iridex Corp: Bleak Financial Performance Raises Concerns for Investors
Iridex Corp, a prominent player in the medical equipment and supplies sector, has recently witnessed a significant decline in its financial performance, leaving investors worried about the company's future prospects. The company's financial results for the May to July 01, 2023 interval reveal a troubling trend that raises serious concerns.
First and foremost, there has been a substantial increase in the company's loss per share, which now stands at $-0.17 per share compared to $-0.14 a year ago. Additionally, this marks a surge in losses from the previous quarter, where the loss per share was reported at $-0.13. Such a decline in ...

1. Iridex Corp Faces Shortfall on Weak Sales in First Quarter of 2023

San Francisco-based Iridex Corp, a medical device manufacturer, recently reported its financial statements for the February to April 01, 2023 time-frame, and the results are not encouraging. The company suffered a loss of $-0.13 per share, compared to $-0.15 per share that it reported in the same quarter last year. Also, compared to the previous quarter, the loss increased from $-0.07 per share to $-0.13 per share.
Furthermore, Iridex Corp's revenue was not any better. The company experienced a double-digit decrease in revenue, with a drop of -10.148% to $13.71 million in this quarter, from $15.25 million in the same period a year prior. Sequentially, the revenue worsened by -9.799% from $15.20 million.<...


Date modified: 2023-11-21T23:28:16+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com